CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 18 No. 5
The Chugh/Baker Article Reviewed 

Nonepithelial Malignancies of the Breast

By SYED A. HODA, MD
Department of Pathology
New York Presbyterian
Hospital/Weill Cornell
Medical Center
New York, New York | May 1, 2004

Chugh and Baker have presented a concise and contemporary review of the common nonepithelial malignancies of the breast, focusing mainly on the management of this heterogeneous group of neoplasms. Needless to say, appropriate management of any neoplasm is entirely dependent on accurate pathologic diagnosis. Due to the rarity of these nonepithelial malignancies of the breast, they commonly present difficulties in pathologic diagnosis. Issues relating to the diagnosis of these tumors may not be obvious to nonpathologists, and deserve comment. Classification of Nonepithelial Malignancies of Breast
The stroma of the breast includes blood vessels, fibroblasts, smooth muscle, peripheral nerves, and last but certainly not least, adipose tissue. A complete list of all possible nonepithelial malignancies of the breast would be a lengthy one and would include angiosarcoma, fibrosarcoma, leiomyosarcoma, peripheral nerve sarcoma, and liposarcoma. Pathologic classification of these tumors remains problematic. One need only note that Chugh and Baker list malignant fibrous histiocytomas among the most common subtypes of breast sarcomas-however, the very existence of malignant fibrous histiocyto ma as a pathologic entity has been questioned.[1] The authors have classified nonepithelial malignancies of the breast into five basic categories: primary breast sarcoma, secondary (therapy-related) sarcoma, phyllodes tumor, primary lymphoma, and angiosarcoma. This classification may be helpful from a clinical perspective but is overly (and overtly) simplistic from a pathologic standpoint. For instance, primary breast sarcomas encompass a complex (and dizzying) array of tumors. Classification of these tumors may be dependent on the pathologist's understanding of histogenesis or differentiation. For example, liposarcoma in the breast is uncommonly primary and most often represents liposarcomatous differentiation in a malignant phyllodes tumor.[2] Clinicopathologic Correlation
The pathologist entrusted with the diagnosis of nonepithelial malignancies of the breast ought to possess all pertinent clinical information. The availability of clinical history, eg, previous sarcoma or radiation, is crucial for accuracy in diagnosis. Some nonepithelial malignancies in the breast could represent metastatic tumors. Radiation has been associated with certain stromal tumors including the so-called malignant fibrous histiocytoma. Information regarding physical examination and radiologic findings may be important in establishing the appropriate pathologic diagnosis. Cutaneous (from skin overlying breast) or osseous (from a rib underlying breast) neoplasms may simulate primary intramammary nonepithelial malignancies. Knowledge of the patient's clinical history is critical for the diagnosis of so-called "atypical vascular lesion"- a lesion described in the skin overlying the breast following irradiation.[ 3] These lesions may be difficult to distinguish from low-grade angiosarcomas. Clinical presentation as a discrete cutaneous lesion, a short interval between irradiation and presentation, and subtle histologic differences are helpful in establishing the apposite diagnosis. Phyllodes Tumor
As Chugh and Baker have indicated, the pathologic diagnosis of phyllodes (fibroepithelial) tumor must be qualified as benign, borderline, or fully malignant-a distinction determined by the tumor's cellularity, stromal overgrowth, mitotic activity, and cytologic atypia. However, the overriding determinant of prognosis is the assessment of margins: The fundamental goal of therapy for all forms of phyllodes tumor is complete excision to prevent recurrence. Second Opinion
Pathologic diagnosis of some forms of nonepithelial malignancies may be challenging. For example, a certain type of epithelial malignancy (metaplastic spindle cell carcinoma) may simulate a nonepithelial malignancy. As a matter of fact, this tumor has been referred to as a "fibromatosislike" carcinoma.[4] The diagnosis of this tumor may require confirmatory immunostaining with high-molecularweight cytokeratin, but above all else, requires awareness of the entity on the part of the pathologist. In terms of incidence, malignancies of epithelial origin vastly outnumber those of nonepithelial (stromal) origin-the latter comprise < 5% of all breast cancers. Owing to their rarity, nonepithelial malignancies are uncommonly encountered by pathologists in routine practice. Rare diagnoses require diagnostic affirmation by ancillary techniques, and may also require a second opinion from an expert well versed in the diagnostic nuances of such neoplasms.[5] Optimistic Note
A notable silver lining in the otherwise dark cloud of nonepithelial malignancies of the breast is the expectation that with the advent of sentinel lymphadenectomy, Stewart- Treves syndrome (ie, angiosarcoma primarily in the upper extremity following lymphedema) has been relegated to the pages of textbooks of medical history. Nonepithelial malignancies of the breast are uncommon. Accurate pathologic diagnosis, crucial for the management of this group of tumors, should always be based on clinical information.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.



RASHMI CHUGH, MD and LAURENCE BAKER, DO


1. Fletcher CD, Gustafson P, Rydholm A, et al: Clinicopathologic re-evaluation of 100 malignant histiocytomas: Prognostic relevance of subclassification. J Clin Oncol 19:3045-3050, 2001.
2. Powell CM, Rosen PP: Adipase differentiation in cystosarcoma phyllades. A study of 14 cases. Am J Surg Pathol 18:720-727, 1994.
3. Fineberg S, Rosen PP: Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol 102:757- 763, 1994.
4. Sneige N, Yaziji H, Mandavilli SR, et al: Low-grade (fibromatosis-like) spindle cell carcinoma of the breast. Am J Surg Pathol 25:1009-1016, 2001.
5. Rosen PP: Review of "outside" pathology before treatment should be mandatory. Am J Surg Pathol 26:1235-1246, 2002.


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Conflicts of Interest in Medicine: What About Ties to Payers?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy